FDA grants orphan drug designation for BMN 250 for the treatment of MPS IIIB

BioMarin announced that the FDA granted orphan drug designation for BMN 250 for the treatment of MPS IIIB. They expect to initiate clinical studies with BMN 250 in mid-2015. Read the full press release here.

This entry was posted in News. Bookmark the permalink.

Comments are closed.